$ARTH
Arch Therapeutics, Inc. Stock $arth

$arth Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-K Financial Statement

#000114420414073579 Filed on December 12, 2014

Income Statement

Concept	2014 Q3	2014	2013 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$860.0K	$3.130M
YoY Change		104.58%
% of Gross Profit
Research & Development	$530.0K	$1.477M
YoY Change		574.95%
% of Gross Profit
Depreciation & Amortization	$0.00	$322.00	$0.00
YoY Change		-45.05%
% of Gross Profit
Operating Expenses	$1.390M	$4.612M	$960.0K
YoY Change	44.79%	164.29%	540.0%
Operating Profit		-$4.612M
YoY Change		164.29%
Interest Expense	$2.020M	$111.1K
YoY Change		2.0%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$7.540M	$0.00
YoY Change
Pretax Income	$640.0K	-$8.140M	-$960.0K
YoY Change	-166.67%	340.0%	405.26%
Income Tax	$0.00	$0.00
% Of Pretax Income	0.0%
Net Earnings	$640.0K	-$8.143M	-$960.0K
YoY Change	-166.67%	339.25%	405.26%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.12
Diluted Earnings Per Share	$8.868K	-$120.6K	-$44.92K
COMMON SHARES
Basic Shares Outstanding	72.08M shares	67.49M shares	59.15M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q3	2014	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$830.0K	$830.0K	$560.0K
YoY Change	48.21%	48.21%	2700.0%
Cash & Equivalents	$833.5K		$557.3K
Short-Term Investments
Other Short-Term Assets	$40.00K	$40.00K	$20.00K
YoY Change	100.0%	100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$877.0K	$880.0K	$1.577M
YoY Change	-44.39%	-44.3%	7612.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00	$0.00	$322.00
YoY Change	-100.0%		-64.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00	$10.06K
YoY Change	-100.0%	-100.0%
Total Long-Term Assets	$0.00	$0.00	$10.38K
YoY Change	-100.0%	-100.0%	1043.61%
TOTAL ASSETS
Total Short-Term Assets	$877.0K	$880.0K	$1.577M
Total Long-Term Assets	$0.00	$0.00	$10.38K
Total Assets	$877.0K	$880.0K	$1.587M
YoY Change	-44.75%	-44.65%	7333.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$175.8K	$180.0K	$314.8K
YoY Change	-44.14%	-41.94%	21.8%
Accrued Expenses	$270.0K	$270.0K	$140.0K
YoY Change	92.86%	92.86%	-60.31%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$2.724M	$2.720M	$455.6K
YoY Change	497.81%	491.3%	-82.15%
LONG-TERM LIABILITIES
Long-Term Debt	$960.0K	$960.0K	$940.0K
YoY Change	2.13%	2.13%	291.67%
Other Long-Term Liabilities	$4.090M	$4.090M	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$5.046M	$5.050M	$944.7K
YoY Change	434.11%	437.23%	291.42%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.724M	$2.720M	$455.6K
Total Long-Term Liabilities	$5.046M	$5.050M	$944.7K
Total Liabilities	$7.769M	$7.770M	$1.400M
YoY Change	454.83%	455.0%	-49.88%
SHAREHOLDERS EQUITY
Retained Earnings	-$12.77M		-$4.632M
YoY Change	175.8%
Common Stock	$5.882M		$60.15K
YoY Change	9680.12%		965.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.892M	-$6.890M	$187.0K
YoY Change
Total Liabilities & Shareholders Equity	$877.0K	$880.0K	$1.587M
YoY Change	-44.75%	-44.65%	7333.07%

Cashflow Statement

Concept	2014 Q3	2014	2013 Q3
OPERATING ACTIVITIES
Net Income	$640.0K	-$8.143M	-$960.0K
YoY Change	-166.67%	339.25%	405.26%
Depreciation, Depletion And Amortization	$0.00	$322.00	$0.00
YoY Change		-45.05%
Cash From Operating Activities	-$970.0K	-$3.349M	-$660.0K
YoY Change	46.97%	133.41%	560.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	3.620M	750.0K
YoY Change	-100.0%	92.91%	650.0%
NET CHANGE
Cash From Operating Activities	-970.0K	-$3.349M	-660.0K
Cash From Investing Activities	0.000	0.000	0.000
Cash From Financing Activities	0.000	3.620M	750.0K
Net Change In Cash	-970.0K	-$3.349M	90.00K
YoY Change	-1177.78%	-857.76%	-309237645312000600.0%
FREE CASH FLOW
Cash From Operating Activities	-$970.0K	-$3.349M	-$660.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q3	us-gaap	Notes Receivable Gross NotesReceivableGross	0	USD
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px 0pt 8pt; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px 0pt 8pt; FONT: 10pt Times New Roman, Times, Serif"> <u>Use of Estimates</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 44pt; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 44pt; FONT: 10pt Times New Roman, Times, Serif"> Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q2	arth	Percentage Of Outstanding Number Of Shares PercentageOfOutstandingNumberOfShares	0.04	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.77	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.34	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0083	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0252	pure
CY2014	arth	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate	0.00	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1361985	shares
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	288000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1101000	USD
CY2014	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y11D
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3000000	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5869212	shares
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	231250	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8637962	shares
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	4645935	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	8637962	shares
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.33
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.40
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.34
CY2014	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	0.36
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	0.34
CY2014	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedWeightedAverageRemainingContractualTerm	P0Y
CY2014	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm	P0Y
CY2014	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm	P0Y
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y5M16D
CY2014	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm	P4Y7M6D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y5M16D
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2750	USD
CY2014	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue	76	USD
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	2750	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	557319	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	833520	USD
CY2013Q3	us-gaap	Notes Receivable Gross NotesReceivableGross	1000000	USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19629	USD
CY2014Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	43470	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	1576948	USD
CY2014Q3	us-gaap	Assets Current AssetsCurrent	876990	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	322	USD
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10062	USD
CY2014Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2013Q3	us-gaap	Assets Assets	1587332	USD
CY2014Q3	us-gaap	Assets Assets	876990	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	314769	USD
CY2014Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	175832	USD
CY2013Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	140840	USD
CY2014Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	267835	USD
CY2013Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2014Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2280000	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	455609	USD
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2723667	USD
CY2013Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	944707	USD
CY2014Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	955766	USD
CY2013Q3	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	0	USD
CY2014Q3	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	100000	USD
CY2013Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2014Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3990000	USD
CY2013Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	944707	USD
CY2014Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5045766	USD
CY2013Q3	us-gaap	Liabilities Liabilities	1400316	USD
CY2014Q3	us-gaap	Liabilities Liabilities	7769433	USD
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	60145	USD
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	72051	USD
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4758742	USD
CY2014Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5810200	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	187016	USD
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	-6892443	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1587332	USD
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	876990	USD
CY2014Q3	us-gaap	Notes Payable NotesPayable	944707	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	55293	USD
CY2014	us-gaap	Interest Expense Debt InterestExpenseDebt	11059	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1735000	USD
CY2011Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	250000	USD
CY2011Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.06	pure
CY2013Q1	arth	Convertible Preferred Stock Value Upon Closing Of Preferred Equity Financing ConvertiblePreferredStockValueUponClosingOfPreferredEquityFinancing	1000000	USD
CY2011Q3	arth	Convertible Preferred Stock Value Upon Closing Of Preferred Equity Financing ConvertiblePreferredStockValueUponClosingOfPreferredEquityFinancing	750000	USD
CY2013Q1	arth	Matured Convertible Notes MaturedConvertibleNotes	50000	USD
CY2012Q3	arth	Matured Convertible Notes MaturedConvertibleNotes	1245000	USD
CY2012Q4	arth	Matured Convertible Notes MaturedConvertibleNotes	50000	USD
CY2014Q3	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	10391693	USD
CY2014	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2850000	USD
CY2014	arth	Fair Value Of Derivative Liabilities In Excess Of Proceeds FairValueOfDerivativeLiabilitiesInExcessOfProceeds	7541693	USD
CY2014	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	4121693	USD
CY2014Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	6270000	USD
CY2013Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2000000	USD
CY2013Q2	arth	Unit Issued Price Per Share UnitIssuedPricePerShare	0.50
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.75
CY2013	arth	Proceeds From Repayments Of Notes Payable Related Parties ProceedsFromRepaymentsOfNotesPayableRelatedParties	-275200	USD
CY2013Q2	arth	Proceeds From Investors In Contemplation Of Merger ProceedsFromInvestorsInContemplationOfMerger	2000000	USD
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60145237	shares
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72076487	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	60145237	shares
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72076487	shares
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	218901	USD
CY2013	us-gaap	Revenues Revenues	0	USD
CY2014	us-gaap	Revenues Revenues	0	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1526075	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3134285	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1477479	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	1744976	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	4611764	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-1744976	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-4611764	USD
CY2013	us-gaap	Interest Expense InterestExpense	108879	USD
CY2014	us-gaap	Interest Expense InterestExpense	111059	USD
CY2013	arth	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	0	USD
CY2014	arth	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	7541693	USD
CY2013	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	0	USD
CY2013	us-gaap	Other Income OtherIncome	64	USD
CY2014	us-gaap	Other Income OtherIncome	0	USD
CY2013	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-108815	USD
CY2014	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3531059	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-1853791	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-8142823	USD
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21366752	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67492823	shares
CY2014	us-gaap	Depreciation Depreciation	322	USD
CY2014	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	92500	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	287927	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	1101286	USD
CY2013	arth	Noncash Interest Expense On Notes Payable NoncashInterestExpenseOnNotesPayable	0	USD
CY2014	arth	Noncash Interest Expense On Notes Payable NoncashInterestExpenseOnNotesPayable	111059	USD
CY2013	arth	Noncash Interest Expense On Convertible Notes Payable NoncashInterestExpenseOnConvertibleNotesPayable	82147	USD
CY2014	arth	Noncash Interest Expense On Convertible Notes Payable NoncashInterestExpenseOnConvertibleNotesPayable	0	USD
CY2013	arth	Noncash Interest Expense On Notes Payable To Related Party NoncashInterestExpenseOnNotesPayableToRelatedParty	25599	USD
CY2014	arth	Noncash Interest Expense On Notes Payable To Related Party NoncashInterestExpenseOnNotesPayableToRelatedParty	0	USD
CY2013	arth	Repayment Of Accrued Interest To Related Parties RepaymentOfAccruedInterestToRelatedParties	-98288	USD
CY2014	arth	Repayment Of Accrued Interest To Related Parties RepaymentOfAccruedInterestToRelatedParties	0	USD
CY2013	arth	Non Cash Expense For Issuance Of Warrants NonCashExpenseForIssuanceOfWarrants	0	USD
CY2014	arth	Non Cash Expense For Issuance Of Warrants NonCashExpenseForIssuanceOfWarrants	3420000	USD
CY2013	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2014	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	94875	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	16321	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	13779	USD
CY2013	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	10062	USD
CY2014	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	56343	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-138937	USD
CY2013	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	91332	USD
CY2014	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	126995	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1434620	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3348502	USD
CY2013	arth	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	2000000	USD
CY2014	arth	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	2624703	USD
CY2014	arth	Proceeds From Repayments Of Notes Payable Related Parties ProceedsFromRepaymentsOfNotesPayableRelatedParties	0	USD
CY2013	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17139	USD
CY2013	us-gaap	Interest Paid InterestPaid	98288	USD
CY2014	us-gaap	Interest Paid InterestPaid	0	USD
CY2013	arth	Promissory Notes Receivable Debt With Warrants Issuance Costs Incurred During Non Cash Or Partial Non Cash Transaction PromissoryNotesReceivableDebtWithWarrantsIssuanceCostsIncurredDuringNonCashOrPartialNonCashTransaction	1000000	USD
CY2014	arth	Promissory Notes Receivable Debt With Warrants Issuance Costs Incurred During Non Cash Or Partial Non Cash Transaction PromissoryNotesReceivableDebtWithWarrantsIssuanceCostsIncurredDuringNonCashOrPartialNonCashTransaction	0	USD
CY2013	arth	Stock Issued During Period Value Exchange Of Debt And Accrued Interest StockIssuedDuringPeriodValueExchangeOfDebtAndAccruedInterest	2470022	USD
CY2014	arth	Stock Issued During Period Value Exchange Of Debt And Accrued Interest StockIssuedDuringPeriodValueExchangeOfDebtAndAccruedInterest	0	USD
CY2013	arth	Stock Issued During Period Value On July2013 StockIssuedDuringPeriodValueOnJuly2013	250000	USD
CY2014Q3	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	50000	USD
CY2014Q3	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	50000	USD
CY2014Q3	us-gaap	Contractual Obligation ContractualObligation	195000	USD
CY2013	arth	Stock Issued During Period Value On August2013 StockIssuedDuringPeriodValueOnAugust2013	500000	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	30186	USD
CY2013	arth	Adjustments To Additional Paid In Capital Grant Of One Warrant To Purchase Shares Of Common Stock Issued With Note Payable AdjustmentsToAdditionalPaidInCapitalGrantOfOneWarrantToPurchaseSharesOfCommonStockIssuedWithNotePayable	55293	USD
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	dei	Entity Registrant Name EntityRegistrantName	Arch Therapeutics, Inc.
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0001537561
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2014Q3	dei	Entity Public Float EntityPublicFloat	18000000	USD
CY2014	dei	Trading Symbol TradingSymbol	ARTH
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	76076487	shares
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4631871	USD
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12774694	USD
CY2012Q3	us-gaap	Stockholders Equity StockholdersEquity	-2772435	USD
CY2013	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	0	USD
CY2013	arth	Stock Issued During Period Value On June2013 StockIssuedDuringPeriodValueOnJune2013	1250000	USD
CY2013	arth	Exchange Of Debt For Common Stock ExchangeOfDebtForCommonStock	2470022	USD
CY2014Q3	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	45000	USD
CY2014Q3	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	50000	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	30186	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	287927	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1101286	USD
CY2013Q4	arth	Payments For Rent Per Square Foot PaymentsForRentPerSquareFoot	26	USD
CY2013Q4	arth	Payments For Rent Monthly Payments PaymentsForRentMonthlyPayments	5031	USD
CY2013Q4	arth	Payments For Security Deposits PaymentsForSecurityDeposits	10062	USD
CY2013	arth	License Maintenance Costs LicenseMaintenanceCosts	25000	USD
CY2014	arth	License Maintenance Costs LicenseMaintenanceCosts	35000	USD
CY2014	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 44pt; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 44pt; FONT: 10pt Times New Roman, Times, Serif"> <u>Concentration of Credit Risk</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 44pt; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 44pt; FONT: 10pt Times New Roman, Times, Serif"> Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	46230	USD
CY2014Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	955766	USD
CY2013Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5991	USD
CY2014Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3925	USD
CY2013Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	5669	USD
CY2014Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	3925	USD
CY2014	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	2066	USD
CY2014Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2066	USD
	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	42	shares
CY2013Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	275200	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	105000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1332955	USD
CY2014Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2731492	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1000000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	32559	USD
CY2014Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	63368	USD
CY2013Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	115171	USD
CY2014Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	501175	USD
CY2013Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	7492	USD
CY2014Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	1568	USD
CY2013Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	35744	USD
CY2013Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1523921	USD
CY2014Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3725705	USD
CY2013Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1523921	USD
CY2014Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3725705	USD
CY2013Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2014Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2014Q3	arth	Convertible Preferred Stock Value Upon Closing Of Preferred Equity Financing ConvertiblePreferredStockValueUponClosingOfPreferredEquityFinancing	1000000	USD
CY2014	arth	Percentage Of Principle Balance Of Notes On Conversion Price Of Notes PercentageOfPrincipleBalanceOfNotesOnConversionPriceOfNotes	0.2	pure
	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2010-08-10
CY2014	arth	Percentage Of Conversion Price Of Convertible Preferred Stock PercentageOfConversionPriceOfConvertiblePreferredStock	0.2	pure
CY2013Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	3486000	USD
CY2014Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	6230000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2800000	USD
CY2014Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	5271000	USD
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	589000	USD
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2202000	USD
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.38
CY2013Q1	arth	Convertible Notes Payable Related Parties Current ConvertibleNotesPayableRelatedPartiesCurrent	105000	USD
CY2010Q4	arth	Cash Bonus CashBonus	500000	USD
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2010Q4	arth	Debt Instrument Convertible Threshold Amount DebtInstrumentConvertibleThresholdAmount	1000000	USD
CY2010Q4	arth	Convertible Preferred Stock Value Upon Closing ConvertiblePreferredStockValueUponClosing	100000	USD
CY2014	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedAggregateIntrinsicValue	0	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2014	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodAggregateIntrinsicValue	0	USD
CY2013Q3	arth	Deferred Tax Assets Capitalized Expenditures DeferredTaxAssetsCapitalizedExpenditures	0	USD
CY2014Q3	arth	Deferred Tax Assets Capitalized Expenditures DeferredTaxAssetsCapitalizedExpenditures	381872	USD
CY2013Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	14645237	shares
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.0024
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.345
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.0024
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.345
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.345
CY2013Q1	arth	Convertible Notes Payable Related Parties Current ConvertibleNotesPayableRelatedPartiesCurrent	1345000	USD
CY2013Q2	arth	Increase In Aggregate Number Of Shares IncreaseInAggregateNumberOfShares	3000000	shares
CY2013	arth	Fully Depreciated Fixed Assets Disposed FullyDepreciatedFixedAssetsDisposed	0	USD
CY2014	arth	Fully Depreciated Fixed Assets Disposed FullyDepreciatedFixedAssetsDisposed	2066	USD
CY2014	arth	Stock Issued During Period Value Restricted Stock For Services StockIssuedDuringPeriodValueRestrictedStockForServices	94875	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	92500	USD
CY2014	arth	Stock Issued During Period Value Private Placement Funding StockIssuedDuringPeriodValuePrivatePlacementFunding	-225297	USD
CY2013	arth	Issuance Of Common Stock And Warrants IssuanceOfCommonStockAndWarrants	2500000	shares
CY2013Q3	arth	Issuance Of Common Stock And Warrants Value Per Share IssuanceOfCommonStockAndWarrantsValuePerShare	0.50
CY2013	arth	Issuance Of Common Stock And Warrants One IssuanceOfCommonStockAndWarrantsOne	500000	shares
CY2013Q3	arth	Issuance Of Common Stock And Warrants Value Per Share One IssuanceOfCommonStockAndWarrantsValuePerShareOne	0.50
CY2013	arth	Issuance Of Common Stock And Warrants Two IssuanceOfCommonStockAndWarrantsTwo	1000000	shares
CY2013Q3	arth	Issuance Of Common Stock And Warrants Value Per Share Two IssuanceOfCommonStockAndWarrantsValuePerShareTwo	0.50
CY2013	arth	Grant Of Warrant To Purchase Common Stock GrantOfWarrantToPurchaseCommonStock	145985	shares
CY2013	us-gaap	Restricted Stock Expense RestrictedStockExpense	0	USD
CY2014	us-gaap	Restricted Stock Expense RestrictedStockExpense	95000	USD

Files In Submission

Name	View Source	Status
0001144204-14-073579-index-headers.html	Edgar Link	pending
0001144204-14-073579-index.html	Edgar Link	pending
0001144204-14-073579.txt	Edgar Link	pending
0001144204-14-073579-xbrl.zip	Edgar Link	pending
arth-20140930.xml	Edgar Link	completed
arth-20140930.xsd	Edgar Link	pending
arth-20140930_cal.xml	Edgar Link	unprocessable
arth-20140930_def.xml	Edgar Link	unprocessable
arth-20140930_lab.xml	Edgar Link	unprocessable
arth-20140930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v395943_10k.htm	Edgar Link	pending
v395943_ex23-1.htm	Edgar Link	pending
v395943_ex3-1.htm	Edgar Link	pending
v395943_ex31-1.htm	Edgar Link	pending
v395943_ex31-2.htm	Edgar Link	pending
v395943_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARTH
Arch Therapeutics, Inc. Stock $arth

2014 Q3 Form 10-K Financial Statement

#000114420414073579 Filed on December 12, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTH Arch Therapeutics, Inc. Stock $arth

2014 Q3 Form 10-K Financial Statement

#000114420414073579 Filed on December 12, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTH
Arch Therapeutics, Inc. Stock $arth